Bio-Reference to Offer Natera's NIPD Test | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Reference Laboratories today announced a definitive agreement to offer Natera's non-invasive prenatal diagnostic test.

The test, which detects for trisomy 21, 18, and 13 and certain sex-chromosome abnormalities, will be sold by Bio-Reference's GenPath business unit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.